ROCKET PHARMACEUTICALS, INC.
No SEC Form 4 filings for $RCKT in the last 30 days.
See all $RCKT insider activity →Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.
Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001281895 0001281895 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 R
Over the past 7 days, alphai's AI scored 2 news stories mentioning RCKT (ROCKET PHARMACEUTICALS, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent RCKT coverage spans financial news, technology and corporate actions.
Early post-amendment safety appears to de-risk the pivotal relaunch, improving odds of completing the Phase II program and supporting a future approval path.
Early patient-level safety confirmation after a prior clinical hold reduces near-term binary risk for RP-A501, supporting sentiment into the Aug 6 earnings date.
Management/finance leadership transition is a governance and reporting-control signal, but the filing provides no new financial guidance or operational change.
The PRV monetization is a concrete balance-sheet/cash catalyst and may reduce financing risk while signaling portfolio capital reallocation.
Insider selling is a near-term sentiment signal, but the filing provides no fundamental catalyst or guidance change.
alphai scores every news story that mentions RCKT with an AI model for sentiment and relevance, and aggregates insider trades from ROCKET PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.
5 min readInvesting.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.
3 min readROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001281895 0001281895 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 R
2 min readROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R
2 min readShah Gaurav (CEO) sold 55,684 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.09 ($0.17M total) on 2026-05-21.
1 min readRocket Pharmaceuticals (RCKT) recently held its 2026 Annual Meeting of Stockholders, where shareholders re-elected the full slate of seven directors and ratified EisnerAmper LLP as the independent registered accounting firm. Investors also approved executive compensation and a stock option exchange program, signaling support for governance continuity and talent retention. While TipRanks' AI Analyst "Spark" rates RCKT as Neutral due to weak financials, the company benefits from strong corporate catalysts like FDA accelerated approval and significant non-dilutive funding.
4 min readWedbush Securities has reiterated its "outperform" rating for Rocket Pharmaceuticals, citing the company's progress in its cardiac gene therapy pipeline. The broker believes the stock is significantly undervalued, maintaining a $16 price target against the current trading price of $4.97. Key advancements include the resumption of patient dosing for its Phase 2 Danon disease study and the upcoming Phase 1 trial for RP-A701 targeting BAG3-dilated cardiomyopathy.
4 min readRocket Lab today completed its second launch in two days from its launch sites in two hemispheres, setting a new annual launch record for the Company.
3 min readRocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
3 min readOn Tuesday, the U.S. Food and Drug Administration ( FDA ) accepted Rocket Pharmaceuticals, Inc.'s ( NASDAQ:RCKT ) resubmission of the Biologics License Application ( BLA ) for Kresladi ( marnetegragene autotemcel.
3 min read
